An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies
Phase 3 – large-scale trial before approval
Conditions:
B-cell malignancies
Sponsor: BeOne Medicines AG
trial.available_in:
БГ
Overview
Trial status: Authorised
Progression-free Survival per investigator assessment, Duration of Response per investigator assessment, Overall Survival
The primary endpoint of the study is safety as assessed by incidence of all TEAEs and SAEs.
Description
Progression-free Survival per investigator assessment, Duration of Response per investigator assessment, Overall Survival
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 343 participants
БГ